ClearPoint Neuro to Present at the B. Riley Securities 2023 Institutional Investor Conference
Rhea-AI Summary
ClearPoint Neuro (Nasdaq: CLPT), a global therapy-enabling platform company focused on brain navigation and delivery, has announced its participation in the B. Riley Securities 2023 Institutional Investor Conference. The company's management team is scheduled to present on Wednesday, May 24, 2023, at 8:15 a.m. Pacific Time.
This conference provides an opportunity for ClearPoint Neuro to showcase its innovative technologies and business strategies to institutional investors. As a leader in brain-focused therapies, the company's presentation is likely to generate significant interest among attendees and potential investors in the medical technology sector.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CLPT gained 0.12%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOLANA BEACH, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the B. Riley Securities 2023 Institutional Investor Conference on Wednesday, May 24, 2023 at 8:15 a.m. Pacific Time.
About ClearPoint Neuro
ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Applications of the Company’s current product portfolio include deep brain stimulation, laser ablation, biopsy, and delivery of drugs, biologics, and gene therapy to the brain. The ClearPoint Neuro Navigation System has FDA clearance, is CE-marked, and is installed in over 65 active sites in the North America, Europe, and South America. ClearPoint Neuro is partnered with more than 50 pharmaceutical/biotech companies, academic centers, and contract research organizations providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, more than 6,000 procedures have been performed and supported by the Company’s field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.
ClearPoint Neuro Contact:
Danilo D’Alessandro, Chief Financial Officer
(949)-900-6833
info@clearpointneuro.com
Caroline Corner, Investor Relations
ir@clearpointneuro.com
FAQ
When is ClearPoint Neuro (CLPT) presenting at the B. Riley Securities 2023 Institutional Investor Conference?
What does ClearPoint Neuro (CLPT) specialize in?
Where is the B. Riley Securities 2023 Institutional Investor Conference being held?
What is the significance of ClearPoint Neuro (CLPT) presenting at this conference?
